RESUMEN
The potential of peptide receptor radionuclide therapy (PRRT) is described in a case of recurrent inoperable phosphaturic mesenchymal tumor causing osteomalacia in the left basiocciput, for which the patient had undergone surgery twice previously. After one cycle of PRRT, there was good symptomatic improvement, with a modest reduction in uptake on both 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT suggesting a favorable response. Hence, treatment with a second cycle was considered. Being somatostatin receptor-avid, this rare group of tumors when inoperable or recurrent may potentially be targeted with PRRT. Well-tolerated and noninvasive, PRRT could evolve as a promising targeted treatment approach in this clinical setting. In summary, tumor-induced osteomalacia with 68Ga-DOTATATE-avid inoperable or recurrent tumor can be considered a potential clinical application for PRRT beyond neuroendocrine tumors.
Asunto(s)
Neoplasias de Tejido Conjuntivo/etiología , Neoplasias de Tejido Conjuntivo/radioterapia , Octreótido/análogos & derivados , Compuestos Organometálicos , Receptores de Somatostatina/metabolismo , Cráneo , Femenino , Humanos , Persona de Mediana Edad , Neoplasias de Tejido Conjuntivo/diagnóstico por imagen , Neoplasias de Tejido Conjuntivo/metabolismo , Osteomalacia , Síndromes Paraneoplásicos , Tomografía Computarizada por Tomografía de Emisión de Positrones , RecurrenciaRESUMEN
Desmoid tumors are non-metastatic mesenchymal tumors with an aggressive local growth. Depending on the anatomic location, morbidity varies. We report of a patient with a desmoid tumor of the right shoulder which was treated in our department by surgical excision, plastic-surgical wound closure and postoperative adjuvant radiation.
Asunto(s)
Fibromatosis Agresiva/cirugía , Músculo Esquelético/cirugía , Neoplasias de Tejido Conjuntivo/cirugía , Hombro/cirugía , Colgajos Quirúrgicos , Braquiterapia , Fibromatosis Agresiva/radioterapia , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de Tejido Conjuntivo/radioterapia , Hombro/patología , Técnicas de Cierre de HeridasRESUMEN
BACKGROUND: The aim was to review a single-institution experience of a prospective treatment protocol for soft tissue sarcoma of the extremity and trunk wall, with particular focus on the smallest surgical margin leading to local control. METHODS: The study included 270 patients who had surgery for soft tissue sarcoma at Helsinki University Central Hospital between 1987 and 1997. Resection margins were measured prospectively from tumour specimens. Radiotherapy was administered if the smallest margin measured less than 2.5 cm, irrespective of tumour grade. RESULTS: With a median follow-up of 6.6 years, the 5-year local control rate was 76.4 per cent. On multivariable analysis, the smallest surgical margin around the sarcoma (after radiotherapy) was prognostic for local control. A margin of at least 2.5 cm was associated with a local recurrence-free rate of 89.2 per cent at 5 years. Tumour size, depth or grade and patient's age had no independent prognostic effect on local control. CONCLUSION: Surgical margin had independent prognostic value for local control. A surgical margin of 2-3 cm provided reasonable local control of soft tissue sarcoma, even without radiotherapy. Radiotherapy is recommended for smaller margins, irrespective of tumour grade.
Asunto(s)
Neoplasias de Tejido Conjuntivo/cirugía , Sarcoma/cirugía , Pared Abdominal , Adulto , Anciano , Amputación Quirúrgica/estadística & datos numéricos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Protocolos Clínicos , Extremidades , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/tratamiento farmacológico , Recurrencia Local de Neoplasia/radioterapia , Recurrencia Local de Neoplasia/cirugía , Neoplasias de Tejido Conjuntivo/tratamiento farmacológico , Neoplasias de Tejido Conjuntivo/radioterapia , Estudios Prospectivos , Radioterapia Adyuvante , Sarcoma/tratamiento farmacológico , Sarcoma/radioterapia , Resultado del TratamientoRESUMEN
Between 1966 and 2001, 1254 patients underwent excision of a bone tumour with endoprosthetic replacement. All patients who had radiotherapy were identified. Their clinical details were retrieved from their records. A total of 63 patients (5%) had received adjunctive radiotherapy, 29 pre-operatively and 34 post-operatively. The mean post-operative Musculoskeletal Tumor Society scores of irradiated patients were significantly lower (log-rank test, p = 0.009). The infection rate in the group who had not been irradiated was 9.8% (117 of 1191), compared with 20.7% (6 of 29) in those who had pre-operative radiotherapy and 35.3% (12 of 34) in those who radiotherapy post-operatively. The infection-free survival rate at ten years was 85.5% for patients without radiotherapy, 74.1% for those who had pre-operative radiotherapy and 44.8% for those who had post-operative radiotherapy (log-rank test, p < 0.001). The ten-year limb salvage rate was 89% for those who did not have radiotherapy and 76% for those who did (log-rank test, p = 0.02). Radiotherapy increased the risk of revision (log-rank test, p = 0.015). A total of ten amputations were necessary to control infection, of which nine were successful. Radiotherapy may be necessary for the treatment of a bone sarcoma but increases the risk of deep infection for which amputation may be the only solution.
Asunto(s)
Neoplasias Óseas/radioterapia , Neoplasias de Tejido Conjuntivo/radioterapia , Infecciones Relacionadas con Prótesis/etiología , Traumatismos por Radiación/complicaciones , Sarcoma/radioterapia , Amputación Quirúrgica/estadística & datos numéricos , Neoplasias Óseas/cirugía , Femenino , Humanos , Masculino , Neoplasias de Tejido Conjuntivo/cirugía , Radioterapia Adyuvante/efectos adversos , Factores de Riesgo , Sarcoma/cirugía , Resultado del TratamientoRESUMEN
PURPOSE: We have investigated the antitumor effect of photodynamic therapy (PDT), using Photofrin as the photosensitizer, combined with low-dose cisplatin (CDDP) on NR-S1 mouse squamous cell carcinoma. MATERIALS AND METHODS: CDDP (5 mg/kg body weight) was injected intraperitoneally either 1 hour or 3 hours prior to PDT or immediately afterward. Twenty-four hours after each protocol, the antitumor effects were evaluated by percentage area of the tumor necrosis in hematoxylin-eosin stained specimens as well as terminal deoxynucleotidyl transferase-mediated d-UTP nick-end labeling indices. Furthermore, the tumor sizes were evaluated at 3, 7, and 10 days after each protocol. RESULTS: The antitumor effect of PDT was enhanced by administration of CDDP 3 hours before PDT, whereas the administration of CDDP 1 hour before PDT or immediately after PDT did not potentiate a PDT antitumor effect. CONCLUSION: Administration of low-dose CDDP 3 hours before PDT appears to be a useful treatment modality.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Escamosas/tratamiento farmacológico , Carcinoma de Células Escamosas/patología , Cisplatino/administración & dosificación , Éter de Dihematoporfirina/administración & dosificación , Fotoquimioterapia/métodos , Fármacos Sensibilizantes a Radiaciones/administración & dosificación , Animales , Antineoplásicos/administración & dosificación , Carcinoma de Células Escamosas/radioterapia , Etiquetado Corte-Fin in Situ , Terapia por Luz de Baja Intensidad , Masculino , Ratones , Ratones Endogámicos C3H , Necrosis , Neoplasias de Tejido Conjuntivo/tratamiento farmacológico , Neoplasias de Tejido Conjuntivo/radioterapia , Radioterapia Adyuvante , Estadísticas no Paramétricas , Tejido Subcutáneo/patología , Resultado del Tratamiento , Carga Tumoral/efectos de los fármacosRESUMEN
PURPOSE: The practice policy at the University of Washington has been to employ fast neutron radiotherapy for soft tissue sarcoma lesions with prognostic features predictive for poor local control. These include gross residual disease/inoperable disease, recurrent disease, and contaminated surgical margins. Cartilaginous sarcomas have also been included in this high-risk group. This report updates and expands our previously described experience with this approach. METHODS AND MATERIALS: Eighty-nine soft tissue sarcoma lesions in 72 patients were treated with neutron radiotherapy in our department between 1984 and 1996. Six patients, each with solitary lesions, were excluded from analysis due to lack of follow-up. Seventy-three percent were treated with fast neutron radiation alone, the rest with a combination of neutrons and photons. Median neutron dose was 18.3 nGy (range 4.8-22). Forty-two patients with solitary lesions were treated with curative intent. Thirty-one patients (including 7 previously treated with neutrons) with 41 lesions were treated with the goal of local palliation. Tumors were predominantly located in the extremity and torso. Thirty of 35 (85%) of curative group patients treated postoperatively had close or positive surgical margins. Thirty-four (82%) lesions treated for palliation were unresectable. Thirty-five patients (53%) were treated at the time of recurrence. Median tumor size at initial presentation was 8.0 cm (range 0.6-29), median treated gross disease size was 5.0 cm (range 1-22), and 46/69 evaluable lesions (67%) were judged to be of intermediate to high histologic grade. Fourteen patients (21%) had chondrosarcomas. RESULTS: Median follow-up was 6 months (range 2-47) and 38 months (range 2-175) for the palliative and curative groups, respectively. Kaplan-Meier estimates were obtained for probability of local relapse-free survival (68%), distant disease-free survival (59%), cause-specific survival (68%), and overall survival (66%) at 4 years for the curatively treated group. For the palliatively treated group, estimated local relapse-free survival at 1 year was 62%. Log-rank analysis of the curative group revealed recurrent disease to be the only risk factor predictive for significantly worse local and distant disease-free survival. Intermediate-/high-grade histology was predictive for inferior overall survival. Effective clinical response was documented for 21/27 (78%) lesions treated palliatively. Ten patients (15%) experienced serious chronic radiation-related complications. All of these patients had clinical situations requiring delivery of high neutron doses and/or large radiotherapy fields. CONCLUSION: Fast neutron radiotherapy is locally effective for soft tissue and cartilaginous sarcomas having well-recognized high-risk features. Results in the palliative setting appear to be particularly encouraging, with neutrons frequently providing significant symptomatic response for gross disease, with minimal serious chronic sequelae. Fast neutron radiotherapy should be considered in patients at high risk for local recurrence in both the curative and palliative settings.
Asunto(s)
Neutrones Rápidos/uso terapéutico , Neoplasias de Tejido Conjuntivo/radioterapia , Sarcoma/radioterapia , Neoplasias de los Tejidos Blandos/radioterapia , Adulto , Anciano , Anciano de 80 o más Años , Cartílago/patología , Supervivencia sin Enfermedad , Neutrones Rápidos/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de Tejido Conjuntivo/patología , Cuidados Paliativos , Estudios Retrospectivos , Sarcoma/patología , Neoplasias de los Tejidos Blandos/patologíaRESUMEN
Between 1960 and 1985, 30 patients with solitary plasmacytomas were treated with radiotherapy at the University of Iowa: 13 patients with extramedullary plasmacytomas (EMP) and 17 with solitary plasmacytomas of bone (SPB). The local control rates were 92% for patients with EMP and 88% for those with SPB. Two of nine patients (22%) with EMP treated to the primary tumor only developed regional lymph node metastasis, indicating the need for elective irradiation of this area. The most common pattern of failure in both groups was progression to multiple myeloma. This occurred in 23% of the patients with EMP and 53% of those with SPB. The time course of progression to multiple myeloma differed for the two groups. All of those who progressed to multiple myeloma in the EMP group did so within 2 years, whereas a significant number of those in the SPB group progressed more than 5 years after initial therapy. None of five patients who received adjuvant chemotherapy in the SPB group progressed to multiple myeloma, compared to 75% (9/12) of the patients who did not receive chemotherapy.